Lantern Pharma Inc. (LTRN)
Nasdaq · Healthcare · Biotechnology
$0.9401+9.30%as of Oct 6, 2026, 7:35 AM ET
- Market cap
- $14.0M
- 52-week range
- $0.838 – $4.70
- 52-week change
- −81.10%
- EPS (trailing)
- −$1.63
- Next earnings
- Nov 11, 2026
Fiscal year to Dec 2025
- Net income
- −$17.1M
- Diluted EPS
- −$1.57
- Free cash flow
- −$15.7M
From the company’s annual report on SEC EDGAR.
About Lantern Pharma Inc.
Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1a clinical trial for the treatment of advanced or metastatic solid tumors, or unresectable or recurrent GBM, solid tumor, such as pancreatic, breast, bladder, and lung cancers, as well as glioblastoma and other central nervous system (CNS) cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company also develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and several rare pediatric CNS cancers. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment.
Headquarters: Dallas, United States · 16 employees · lanternpharma.com